Cell Therapy and Gene Therapy: A Case Study on Scaling Up for Commercial Manufacturing, New Webinar Hosted by Xtalks

Xtalks Life Science Webinars

There are two new players on the biologics industry block – cell therapy and gene therapy. Join Mucahit Agirtmis, MES Consultant at Werum IT Solutions for a live session on Thursday, April 26, 2018 at 1 p.m. EDT as he discusses how cell and gene therapies differ from pharmaceuticals and learn about the challenges to achieving commercial manufacturing.

Imagine you are an up-and-coming cell therapy company. You have gone through the exploration phase, with all of its complexities and are in the process of finalizing a breakthrough treatment. At this point, you begin to consider how you can get that cell therapy to a commercial manufacturing setting, with all the tools and systems in place to support the process. The tools and systems that worked well for you in the past may not necessarily work moving forward. There will be a need to consider new tools and new ways of doing things within the company to be successful moving forward.

As the vision of achieving commercial manufacturing becomes clearer, there have to be some major considerations on ways to improve and streamline the manufacture of cell and gene therapies. Some of the considerations include:

  • Cost of production
  • Ability to ensure that these lifesaving drugs are delivered to the patient on time
  • Elimination of paper from the shop floor
  • Preserving the chain of identity throughout the entire process
  • Reduction of manual processes to reduce human error and the effort required to scale
  • Increased quality through standardization of processes
  • Coordination of supply chain tracking
  • Process optimization – product to patient feedback loop
  • Raw material quality – how to control for differing patient health samples
  • Regulatory filing

A unique requirement for cell and gene therapy companies is that the development processes up to commercial manufacturing are not sequential as with other industries. It is a continuously evolving process, where updates are consistently being made in a positive feedback loop. Even after a path to manufacturing has been realized, the improvement process continues with major considerations still at play.

Join us as we walk along the journey of two companies who started from similar beginnings but diverged in the decisions they made on how to scale into commercial manufacturing for their respective cell and gene therapies. The decisions they made around these major considerations and the tools they used to address them will have a lasting impact on the success of their treatment, from scale-up of a developmental therapy to long after the therapy has been approved and is used in patients.

For more information about this complimentary event, visit: Cell Therapy and Gene Therapy: A Case Study On Scaling Up For Commercial Manufacturing

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com.

For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar.

Contact:
​Nima Rajan
Tel: +1 (416) 977-6555 ext 352
​Email: nrajan@xtalks.com

Source: Xtalks


Categories: Pharmaceuticals and Biotech, Production and Manufacturing

Tags: biologics, cell Therapy, commercial manufacturing. process optimization, gene therapy, regulatory filing, Werum, Xtalks


Additional Images

Additional Links

About Xtalks

View Website

Xtalks is a leading provider of educational webinars to the global life science, food and medical device community.